MSDC-0160 for Parkinson’s Disease

MSDC-0160 is an insulin sensitizer being developed by Metabolic Solutions Development Company (MSDC) of Kalamazoo, Michigan, to treat Parkinson’s disease. MSDC-0160 was originally intended to treat type 2 diabetes. However, the Van Andel Research Institute recognized its potential as a treatment for neurodegenerative disorders such as Parkinson’s.

How MSDC-0160 works

Research increasingly supports the idea that mitochondrial dysfunction might be a key feature of Parkinson’s. Mitochondria, an essential component of cells, are responsible for converting food into energy, as well as for signaling. In Parkinson’s patients, a mitochondrial sensor called mTOR is frequently over-activated in the brain. This prevents the cell from reacting appropriately to threats, such as the buildup of the harmful alpha-synuclein protein, which happens in those with Parkinson’s. The mTOR sensor is activated by a protein called mitochondrial pyruvate carrier (MPC), which carries the pyruvate molecule into the mitochondria to be converted into energy.

MSDC-0160 is part of a recently discovered class of insulin sensitizers called mTOR modulators, which are believed to reduce mTOR activity by regulating MPC.

It is anticipated that MSDC-0160 could prevent or reverse the dyskinesia, or involuntary movements, caused by levodopa, which is prescribed to many Parkinson’s patients. MSDC-0160 has the potential to become the first Parkinson’s treatment with neuroprotective properties. Researchers hope it could slow the progression of the disease rather than just mask its symptoms.

MSDC-0160 in clinical trials

MSDC-0160 has been tested in pre-clinical studies using two different mouse models of Parkinson’s. The drug showed significant neuroprotective and anti-inflammatory effects in the mice, while reducing alpha-synuclein clumping. The results appeared in Science Translational Magazine.

Researchers hope to proceed to clinical trials in people with Parkinson’s disease in 2017. MSDC-0160 has already been tested in Phase 2 clinical trials for patients with both type 2 diabetes (NCT01103414) and Alzheimer’s disease (NCT01374438). Neither trial led to severe side effects. Results of these trials were published in the scientific journals Clinical Pharmacology & Therapeutics and Current Alzheimer Research.

Note: Parkinson’s News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums